Previous Close | 5.44 |
Open | 5.41 |
Bid | 5.30 x 0 |
Ask | 5.33 x 0 |
Day's Range | 5.29 - 5.48 |
52 Week Range | 4.35 - 5.75 |
Volume | |
Avg. Volume | 78,187 |
Market Cap | 536.201M |
Beta (5Y Monthly) | 0.49 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.16 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.64 |
MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on Business magazine’s fifth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity. The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to
Last week saw the newest full-year earnings release from Knight Therapeutics Inc. ( TSE:GUD ), an important milestone...
Knight Therapeutics ( TSE:GUD ) Full Year 2023 Results Key Financial Results Revenue: CA$328.2m (up 12% from FY 2022...